Lanreotide Acetate Patent Expiration
Lanreotide Acetate is used for treating acromegaly and neuroendocrine tumors. It was first introduced by Ipsen Pharma Biotech Sas
Lanreotide Acetate Patents
Given below is the list of patents protecting Lanreotide Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Somatuline Depot | US5595760 | Sustained release of peptides from pharmaceutical compositions |
Mar 08, 2020
(Expired) | Ipsen Pharma |
Lanreotide Acetate's Family Patents
Explore Our Curated Drug Screens
Lanreotide Acetate Generic API Manufacturers
Several generic applications have been filed for Lanreotide Acetate.
Given below is the list of companies who have filed for Lanreotide Acetate generic, along with the locations of their manufacturing plants worldwide.
1. INVAGEN PHARMS
Invagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Lanreotide Acetate. Given below are the details of the strengths of this generic introduced by Invagen Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) | solution | Prescription | SUBCUTANEOUS | AB | May 21, 2024 |
| EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) | solution | Prescription | SUBCUTANEOUS | AB | May 21, 2024 |
| EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) | solution | Prescription | SUBCUTANEOUS | AB | May 21, 2024 |